This outward-looking proposal brings together stakeholders from multiple sectors in Australia and the UK to create, use and share better understandings of how to measure NCD-relevant green space qualities. These qualities will be tested with robust measures of mental ill-health and cardiometabolic diseases in Sydney, Wollongong, Glasgow and Edinburgh. This new evidence will be used in the co-design of green space quality policy options intended to promote healthier communities for all.
A Vision Of Healthy Urban Design For NCD Prevention
Funder
National Health and Medical Research Council
Funding Amount
$608,911.00
Summary
We are living in a new city era with new risks for health, and new ways to understand them. This project will combine state-of-the art methods in computer vision and artificial intelligence alongside co-creation of a web-based toolkit for action for use by city planners and urban designers that demonstrate practical pathways Improving our understanding of the strengths and limitations of existing city designs to ensure they are safe, clean, healthy, and sustainable.
COmBining Memantine And Cholinesterase Inhibitors In Lewy Body Dementia Treatment Trial (COBALT)
Funder
National Health and Medical Research Council
Funding Amount
$1,218,120.00
Summary
Many people who have been diagnosed with dementia with Lewy bodies or Parkinson’s disease dementia will be prescribed drugs known as acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine) to help with their symptoms. This research trial, known as COBALT, is designed to find out whether there is any benefit from taking the drug memantine as well. Australian and UK researchers are collaborating on this trial which will recruit eligible participants from both countries.
GloBal RetinAl Imaging CoNSorTium FOR AzheiMer's Disease (BRAINSTORM)
Funder
National Health and Medical Research Council
Funding Amount
$393,099.00
Summary
The retina of the eye displays features of Alzheimer's disease (AD). We have developed a new way to take photos of the eye with a rainbow-coloured flash to detect signs of AD. We now want to test how this and other eye imaging methods compare with brain scans and spinal fluid tests to identify people who are at risk of AD. We will use clinical studies, artificial intelligence, mouse models of AD and donated human tissues to achieve our aims. Our goal is to improve AD detection and care.
E-DADS: Early Detection Of Alzheimer’s Disease Subtypes
Funder
National Health and Medical Research Council
Funding Amount
$488,725.00
Summary
Alzheimer's disease manifests differently in different people. Some people may get the disease at younger ages or they may progress in the disease much faster than others. This grant aims to use large amounts of data from around the world to understand why these differences exist. This knowledge will be converted into a tool where data from a specific individual can be used to forecast if and when they will get the disease and how fast that disease will progress and how it could be prevented.